Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RHB-104 in active Crohn's disease (MAPUS2)
NCT03009396Phase 3Completed
- Sponsor
- RedHill Biopharma
- Start
- Mar 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 7
01
Overview
A Phase 3 trial of RHB-104 in Crohn's disease, sponsored by RedHill Biopharma. Started Mar 2017; status: completed.
02
Drugs
RHB-104
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03009396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03009396.